Syntekabio Partners with PDC Line Pharma to Develop Targeted Cancer Vaccine
Seoul, 2023.09.26 14:10 –
In a significant move towards advancing cancer treatment, Syntekabio, a leading AI drug development company, has announced its collaboration with PDC Line Pharma (PDC), a Chinese immunotherapy vaccine development company from Belgium. The partnership aims to develop a targeted cancer vaccine for customized treatment.
PDC Line Pharma specializes in the development of immuno-anti-cancer vaccines, leveraging its unique vaccine platform technology based on the plasmacytoid dendritic cell line (PDC line). Notably, the company is the first in Europe to proceed with a KOSDAQ listing process through its exceptional treatment technology. As part of its neo PDC pipeline development, PDC is currently conducting phase 1 and 2 clinical trials for patients with non-small cell lung cancer.
The joint research agreement between Syntekabio and PDC will combine PDC’s ‘PDC*’ anti-cancer immune vaccine platform technology with Syntekabio’s ‘NEO-ARS’ neoantigen prediction technology. This promising collaboration aims to develop a case study for a patient-specific cancer vaccine within the year, with a focus on a blood cancer origin (leukemia) using an HLA-A2+ cell line. The successful incorporation of NEO-ARS® technology into the PDC vaccine platform will lay the foundation for the development of a neo PDC pipeline.
With a specific focus on melanoma and non-small cell lung cancer, PDC’s existing off-the-shelf treatments involve the use of antigen-loaded presenting cells containing well-known common tumor antigen peptides. Following this agreement, PDC’s innovative dendritic cell vaccine technology will be applied to Syntekabio’s discovery of patient-specific neoantigen peptides that target cancer-specific antigens (TSAs). This promising collaboration is expected to pave the way for the joint research and development of an effective anti-cancer vaccine.
CEO of PDC Line Pharma, Eric Alliwer, expressed his satisfaction with the collaboration, stating, “Syntekabio’s NEO-ARS neoantigen prediction technology perfectly complements our PDC line platform technology. We are excited to collaborate with Syntekabio in the development of a personalized neoantigen-based anticancer vaccine.” Syntekabio CEO Jeong Jong-seon also expressed enthusiasm, emphasizing the significance of PDC’s proven safety and clinical efficacy in their anti-cancer vaccine platform. He added that the incorporation of NEO-ARS into joint research with PDC will not only contribute to establishing a development strategy for treatment candidates but will also expand the utility of NEO-ARS.
As the fight against cancer continues to evolve, the collaboration between Syntekabio and PDC Line Pharma represents a significant step forward in developing targeted cancer vaccines for more effective and personalized treatments.
Contact: nylee54@newspim.com
Industry | 2023.09.26 14:10
[서울=뉴스핌] Reporter Lee Na-young = Syntekabio, a company specializing in the development of new AI drugs, announced on the 26th that it has signed a joint research agreement (MOU) with PDC Line Pharma (PDC), a Chinese immunotherapy vaccine development company Belgium, to develop a cancer vaccine for targeted treatment.
PDC Line Pharma is a Belgian immuno-anti-cancer vaccine development company and possesses an immuno-anti-cancer vaccine platform technology based on the plasmacytoid dendritic cell line (PDC line). Based on this vaccine technology, we are pursuing the development of a neo PDC pipeline that targets neoantigens, and we are proceeding with the KOSDAQ listing process through a special treatment technology, the first European company to do so.
Currently, phase 1 and 2 clinical trials are being conducted for patients with non-small cell lung cancer, and the vaccine platform is being verified by evaluating the safety, immunogenicity and efficacy of therapeutic candidates that n targeting lung tumor associated antigens (TAA). cancer
Logo Syntekabio. [사진=신테카바이오]
Through this business agreement, we will start developing a cancer vaccine for customized treatment by combining PDC’s ‘PDC*’ anti-cancer immune vaccine platform technology and Syntekabio’s ‘NEO-ARS’ neoantigen prediction technology. do this.
Both companies aim to complete a case study using an HLA-A2+ cell line of blood cancer origin (leukemia) within the year. After reviewing the adequacy and effectiveness of incorporating NEO-ARS® technology into the PDC vaccine platform, collaborative research to develop a neo PDC pipeline will be discussed.
The anti-cancer vaccine candidate for melanoma and the anti-cancer vaccine candidate for non-small cell lung cancer studied at PDC are off-the-shelf treatments that contain antigen-loaded presenting cells with known common tumor antigen peptides. After this business agreement, when research collaboration between the two companies begins in earnest, PDC’s dendritic cell vaccine technology will be applied to the patient-specific neoantigen peptide discovered by Syntekabio that targets cancer-specific antigens (TSAs) that are differentially expressed in It is expected that this will lead to joint research and development of a therapeutic anti-cancer vaccine.
PDC Line Pharma CEO Eric Alliwer said, “Syntekabio’s NEO-ARS neoantigen prediction technology complements the PDC line platform technology,” and added, “We will collaborate with Syntekabio to develop a personalized neoantigen-based anticancer vaccine.” “I’m very happy,” he said.
Syntekabio CEO Jeong Jong-seon said, “We are pleased to join forces with PDC, which has an anti-cancer vaccine platform that has been meaningfully confirmed in terms of safety and clinical efficacy.” He added, “NEO-ARS was incorporated into the PDC Line* in joint research with PDC. “If a patient-tailored anti-cancer vaccine is developed after this, it will not only contribute to establishing a development strategy for treatment candidates, but will also be a positive opportunity in terms of expanding the utility of NEO-ARS,” he said.
nylee54@newspim.com
#Syntekabio #Belgiums #PDC #Line #Pharma #jointly #research #patienttailored #cancer #vaccine
